TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01455389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOTAP:Chol-TUSC2
Description: Starting Dose 0.045 mg/kg by vein on day 1 of each 21 day cycle; Phase II is Maximum Tolerated Dose from Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Starting Dose 100 mg by mouth each day of a 21 day cycle (except for first week of Cycle 1, if enrolled in Phase II delayed-schedule group). Phase II is Maximum Tolerated Dose from Phase I.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 8 mg orally 24 and 12 hours and 20 mg by vein 30 minutes before DOTAP:Chol-TUSC2 treatment followed by 8 mg orally at 12, 24 and 36 hours after treatment (total number doses = 5).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: 50 mg by mouth or by vein 30 minutes prior to treatment with DOTAP:Chol TUSC2
Study: NCT03333876

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Dilator
Description: Mute is a pair of nasal dilators that fit snugly in the nose of the snorer dilating the nostrils to help reduce or eliminate snoring. This is an over-the-counter (OTC) product and is cleared by FDA for use in the United States. The introduction video for Mute is located at http://mutesnoring.com/how-to-use/.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mandibular Advancement
Description: For purposes of this trial, we will be using an investigational myTAP V, which is not available for commercial use. The changes from the released product are: a vertical offset (+3mm) has been added to the design of the adjustment post and mechanism to improve overall comfort.~myTAPTM is a mandibular advancement device used for snoring relief. The product requires a prescription and is cleared by FDA for use in the United States.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Positional Therapy
Description: Sleep Positional Trainer (SPT) is a small device worn around the chest with an ergonomic band that continuously monitors the sleep position of the snorer. When the snorer is supine, it emits a gentle vibration to remind them to turn to the side to help reduce or eliminate their snoring.
Study: NCT00336700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1500mg/m2 IV over 150 min IV q 2 weeks 4 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg/d Daily, oral 12 months
Study: NCT02639039

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cortisone Injection
Description: Exact location and technique of injection within the region of the involved greater trochanter will be determined by the provider. The number of f/u visits within 6 wks following initiation of treatment will be determined by the provider, but CI is the only treatment.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trigger Point Dry Needling
Description: Exact location of needle insertion, technique and number of penetrations within the region of the involved posterolateral hip will be determined by the provider. The number of f/u visits within 6 wks following initiation of treatment will be determined by the provider, but TDN is the only treatment.
Study: NCT04458805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NX-13 250 mg
Description: Dose escalation in Part A will be conducted in a total of 5 cohorts (Cohorts 1 to 5). Seven participants will be enrolled in each cohort and will be randomized to receive either NX-13 or placebo (ratio 5:2). NX-13 will be administered to Cohort 1 participants at the starting dose of 250 mg. The NX-13 dose will be increased in each new cohort. Five nominal dose levels in the range of 250 to 4000 mg have been selected for evaluation in Part A.~It is anticipated that 3 dose levels will be evaluated in Part B in a total of 3 cohorts (Cohorts 6 to 8). Seven participants will be enrolled in each cohort and will be randomized to receive a single oral dose of either NX-13 or placebo (ratio 5:2), once daily for seven days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose escalation in Part A will be conducted in a total of 5 cohorts (Cohorts 1 to 5). Seven participants will be enrolled in each cohort and will be randomized to receive either NX-13 or placebo (ratio 5:2). NX-13 will be administered to Cohort 1 participants at the starting dose of 250 mg. The NX-13 dose will be increased in each new cohort. Five nominal dose levels in the range of 250 to 4000 mg have been selected for evaluation in Part A.~It is anticipated that 3 dose levels will be evaluated in Part B in a total of 3 cohorts (Cohorts 6 to 8). Seven participants will be enrolled in each cohort and will be randomized to receive a single oral dose of either NX-13 or placebo (ratio 5:2), once daily for seven days.
Study: NCT02004223

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Dose escalation using stereotactic boost
Description: This is a dose escalation study. Participants will be allocated to the current dose level, or if the current dose level has been filled and acceptable toxicity has been established, they will be enrolled into the next dose level.~The first dose level will be 20Gy in 2 fractions to PTV and 25Gy to Gross Target Volume (GTV) if identified. The second dose level will be 22Gy in 2 fractions to PTV and 27.5Gy to GTV if identified. The dose level will be 24 Gy in 2 fractions to PTV and 30Gy to GTV if identified.~Following stereotactic boost, all participants will receive 46Gy in 23 fractions radiotherapy to the prostate / seminal vesicles +/- lymph nodes.
Study: NCT03657069

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blossom
Description: Undergo Implant Breast Reconstruction (IBR) with the Blossom Smart Expander Technology

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breast-Q -Reconstruction module (preoperative) version 2.0 satisfaction with breasts questionnaire
Description: Ancillary studies
Study: NCT04105608

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-fiber vegetarian meal
Description: The intervention consisted in the administration of a high fiber vegetarian meal prepared by our research group staff.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean-like meal
Description: The intervention consisted in the administration of a Mediterranean-like meal prepared by our research group staff.
Study: NCT02070510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: For oral administration once daily. Doses of 5 mg and 10 mg, respectively, will be given for 7 days followed by 20 mg administered on days 43-84.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lisinopril
Description: For oral administration. A single dose of 20 mg is administered three times either alone or conconmitantly with a perpetrator compound (days 1, 15 and 71).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Description: For oral administration. A single dose of 5 mg is administered three times either alone or conconmitantly with a perpetrator compound (days 8, 22 and 78).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: A single dose of SNAC is administered conconmitantly with victim compounds (days 15 and 22).
Study: NCT03175211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 456906
Description: single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose
Study: NCT01244867

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20 micrograms dose H5 VLP
Description: 2 doses given 21 days apart of 20 micrograms of H5 VLP vaccine mixed with Alhydrogel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 micrograms dose H5 VLP
Description: 2 doses given 21 days apart of 30 micrograms of H5 VLP vaccine mixed with Alhydrogel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 45 micrograms dose H5 VLP
Description: 2 doses given 21 days apart of 45 micrograms of H5 VLP vaccine mixed with Alhydrogel

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 45 micrograms non-adjuvanted H5 VLP
Description: 2 doses given 21 days apart of 45 micrograms of H5 VLP vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses given 21 days apart of the placebo
Study: NCT02787499

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIV-1 RNA Resistance Testing
Description: Perform drug resistance on enrollment to guide management of virologic failure
Study: NCT04602286

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Meditation (1 x 20-minute guided audio training)
Description: Participants will complete a single session of 20-minutes online guided audio-delivered training session of one of the four conditions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meditation (1 x 20-minute guided audio training)
Description: Participants will complete a single session of 20-minutes online guided audio-delivered training session of one of the four conditions.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Meditation (1 x 20-minute guided audio training)
Description: Participants will complete a single session of 20-minutes online guided audio-delivered training session of one of the four conditions.
Study: NCT02124824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ-123
Description: Endothelin subtype A antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BQ-123
Description: Endothelin subtype A antagonist
Study: NCT00930020

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline (Borymycin)
Description: oral dose, 200 mg once a day for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo
Description: matched placebo (cornstarch) once a day for 5 days
Study: NCT01218308

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluLaval® Quadrivalent
Description: One intramuscular dose for primed subjects. Two intramuscular doses for unprimed subjects.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix™
Description: Two intramuscular doses for primed subjects. Three intramuscular doses for unprimed subjects.
Study: NCT00526474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Description: 2.5-mg tablet daily for at least 1 year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching tablet daily for at least 1 year
Study: NCT04116333

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endotracheal tube introducer
Description: Use of endotracheal tube introducer with the Macintosh laryngoscope on a manikin during continuous chest compressions with mechanical compression device.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh laryngoscope
Description: Use of the Macintosh laryngoscope on a manikin during continuous chest compressions with mechanical compression device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope
Description: Use of the Macintosh laryngoscope on a manikin during continuous chest compressions with mechanical compression device.
Study: NCT01107145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mefloquine- Artesunate
Description: Tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine
Description: 4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: Tablets containing 250 mg Chloroquine salt given as 4 tablets at once on the first day (or 10 mg/kg) followed by 3 tablets once daily for the next 2 days (or 7,5 mg/kg)
Study: NCT02337491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study: NCT03455517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax and rituximab association

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Venetoclax and rituximab association
Study: NCT04015739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab, Olaparib and Durvalumab (MEDI 4736) combination
Description: Patients will receive a combination of these 3 drugs :~Bevacizumab 15mg/kg q3w IV, Olaparib 300mg BD Per Os; and Durvalumab (MEDI 4736) 1.12g IV q3w
Study: NCT02771275

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Harpoon Medical Device
Description: It is expected that the Harpoon Medical transapical suturing device will be a valuable treatment alternative for patients suffering from mitral valve regurgitation because it can access the left ventricle with a small shaft or via a small valved introducer with a secure anchoring mechanism that can be deployed anywhere on the mitral valve leaflet.
Study: NCT03899727

Intervention type: DEVICE
Intervention: Polysomnography
Description: Polysomnography, also called a sleep study, is a test used to diagnose sleep disorders. Polysomnography records your brain waves, the oxygen level in your blood, heart rate and breathing, as well as eye and leg movements during the study

Intervention type: DEVICE
Intervention: Polysomnography
Description: Polysomnography, also called a sleep study, is a test used to diagnose sleep disorders. Polysomnography records your brain waves, the oxygen level in your blood, heart rate and breathing, as well as eye and leg movements during the study
Study: NCT04951141

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-GPC3 CAR-T cells
Description: A single arm, open-label pilot study is designed to determine the safety and efficacy of anti-GPC3 CAR-T cells in patients with GPC3-positive advanced liver cancer.
Study: NCT01022333

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Diindolylmethane (DIM)
Description: 300 mg per day of DIM for six weeks.
Study: NCT03010072

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low-dose sucroferric oxyhydroxide
Description: 250 mg suroferric oxyhydroxide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: high-dose sucroferric oxyhydroxide
Description: 2000 mg suroferric oxyhydroxide
Study: NCT03006562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous Heparin
Description: 5,000 units of subcutaneous heparin before surgery and then every 8 hours after surgery until discharge from the hospital.
Study: NCT02672072

Intervention type: OTHER
Intervention: Simulation during the study (5-day specific training with dedicated scenario done by an ICU expert simulation team)

Intervention type: OTHER
Intervention: questionnaire to define the presence of job strain at 6 months

Intervention type: OTHER
Intervention: questionnaire to define the presence of job strain at 6 months

Intervention type: OTHER
Intervention: questionnaire to define the presence of job strain at 12 months

Intervention type: OTHER
Intervention: questionnaire to define the presence of job strain at 12 months
Study: NCT02647138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: white noise
Description: exposure to white noise
Study: NCT05635903

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous nebulisation 0.9% saline Aerogen Solo vibrating mesh Nebuliser
Description: Continuous nebulisation of 0.9% saline using the Aerogen Solo vibrating mesh nebuliser

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intermittent nebulisation 0.9% saline Aerogen vibrating mesh Solo Nebuliser
Description: Intermittent nebulisation of 0.9% saline using the Aerogen Solo vibrating mesh nebuliser

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent standard intermittent nebulisation of 0.9% saline Intersurgical Cirrus 2 self sealing Jet Nebuliser
Description: standard intermittent nebulisation of 0.9% saline using the Intersurgical Cirrus 2 self-sealing Jet Nebuliser
Study: NCT02885844

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: INVERTED VISION
Description: The tasks will be performed either with normal or inverted vision (upside down) using commercial off-the-shelf inverting prism goggles
Study: NCT03961867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: S-1 (BSA \<1.25m2, 80 mg; 1.25 to 1.5m2, 100 mg; \>1.5m2,120 mg) divided into two doses /day after breakfast and dinner, 14 days / 3 weeks, totally 16 cycles.~Docetaxel 40mg/m2/3w from the second to the seventh cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: S-1 (BSA \<1.25m2, 80 mg; 1.25 to 1.5m2, 100 mg; \>1.5m2,120 mg) divided into two doses /day after breakfast and dinner, 14 days / 3 weeks, totally 16 cycles.~Oxaliplatin 130mg/m2/3w from the first to the eight cycles.
Study: NCT01774981

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3016859
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3016859
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3016859
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3016859
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3016859
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3016859
Description: Administered IV
Study: NCT00997945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054 (Zibotentan)
Description: 10 mg ZD4054 (Zibotentan) once daily on Day1, Day4 to Day15
Study: NCT02227641

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV/EBV specific T-cell
Description: Peptide stimulated allogeneic T-cells with dual specificity for CMV and EBV
Study: NCT04366245

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hyperimmune plasma
Description: PLASMA OF CONVALESCENT COVID-19

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care for SARS-CoV-2 infection
Description: Standard of care for SARS-CoV-2 infection
Study: NCT02930785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY987517
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application.~(Formulation Code:Z46-104)
Study: NCT03537066

Intervention type: DEVICE
Group type: OTHER
Intervention: CPAP
Description: All patients included will be treated by CPAP
Study: NCT03702660

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GIP(3-30)NH2
Description: Peptide derived from the naturally occuring gut hormone GIP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GIP(3-30)NH2
Description: Peptide derived from the naturally occuring gut hormone GIP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peripheral venous cannulation
Description: Intravenous access for infusions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral venous cannulation
Description: Intravenous access for infusions

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peripheral venous cannulation
Description: Intravenous access for infusions

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Peripheral venous cannulation
Description: Intravenous access for infusions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GLP-1
Description: Peptide infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GLP-1
Description: Peptide infusion
Study: NCT00695227

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Screening for Barrett's Esophagus
Study: NCT02337062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APD421

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01483118

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cinnamon Extract
Description: Purified aqueous abstract of cinnamon in 125mg capsules, which would be taken orally before each meal, for a total of 1,500mg/day for 6 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules containing ground cereal.
Study: NCT01911247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 850 mg once daily
Study: NCT01746719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etodolac Capsules USP 300 mg
Description: 300 mg capsule once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etodolac
Description: 500 mg tablet once a day
Study: NCT02885844

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NORMAL VISON
Description: subject's field of view will be restricted by goggles without lenses in order to be equivalent to the inverted vision one.
Study: NCT05301647

Intervention type: DIAGNOSTIC_TEST
Intervention: Nasal cytology
Description: The cytological technique involves the following moments: sampling, processing, which includes fixation, staining and microscopic observation. Cytological sampling consists in the collection of superficial cells of the nasal mucosa with the help of a sterile swab or a small curette (scraping) in disposable plastic material (Rhino-probe).
Study: NCT00492492

Intervention type: PROCEDURE
Group type: OTHER
Intervention: trans-styloid and intrafocal pinning on the one side

Intervention type: PROCEDURE
Group type: OTHER
Intervention: volar fixed-angle plating on the other side
Study: NCT00129337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bavituximab
Description: Bavituximab is a sterile drug solution supplied in glass bottles. Bavituximab will be intravenously administered over approximately 90 minutes on days 0, 7, 14 and 21 (dosage determined based on dose cohort and body weight).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bavituximab
Description: Bavituximab is a sterile drug solution supplied in glass bottles. Bavituximab will be intravenously administered over approximately 90 minutes on days 0, 7, 14 and 21 (dosage determined based on dose cohort and body weight).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bavituximab
Description: Bavituximab is a sterile drug solution supplied in glass bottles. Bavituximab will be intravenously administered over approximately 90 minutes on days 0, 7, 14 and 21 (dosage determined based on dose cohort and body weight).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bavituximab
Description: Bavituximab is a sterile drug solution supplied in glass bottles. Bavituximab will be intravenously administered over approximately 90 minutes on days 0, 7, 14 and 21 (dosage determined based on dose cohort and body weight).